Pembrolizumab Versus Docetaxel For Previously Treated, PD-L1-positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial.

·2016·DOI

Health Sciences and Innovation

Biomedical Engineering

Cancer Research and Treatment

Cancer Immunotherapy Advances

Role in the Field

Neutralin Health Sciences and Innovation

Neutralin Biomedical Engineering

Neutralin Cancer Research and Treatment

Neutralin Cancer Immunotherapy Advances

Abstract

Citations

4,714

Year

2016

PageRank

4.7 / 10

Relative influence (log-scaled)

Related Papers

10 of 10 papers

Remdesivir For The Treatment Of Covid-19 — Final Report

·2020·6,017 citations

Pembrolizumab Plus Chemotherapy In Metastatic Non–Small-Cell Lung Cancer

·2018·5,096 citations

Pembrolizumab Versus Chemotherapy For PD-L1–Positive Non–Small-Cell Lung Cancer

·2017·7,026 citations

Combined Nivolumab And Ipilimumab Or Monotherapy In Untreated Melanoma

·2015·6,665 citations

Pembrolizumab For The Treatment Of Non–Small-Cell Lung Cancer

·2015·5,299 citations

Pembrolizumab Versus Ipilimumab In Advanced Melanoma

·2015·4,980 citations

Nivolumab In Previously Untreated Melanoma withoutBRAFMutation

·2015·4,846 citations

PD-1 Blockade Induces Responses By Inhibiting Adaptive Immune Resistance

·2014·5,596 citations

Improved Survival With Vemurafenib In Melanoma With BRAF V600E Mutation

·2011·6,903 citations

Improved Survival With Ipilimumab In Patients With Metastatic Melanoma

·2010·13,117 citations